Messenger RNAs (mRNAs) represent a fast-emerging class of biotherapeutics. They hold considerable promise, offering new opportunities for targeted treatment and flexible manufacturing, as was recently demonstrated by the rapid development of mRNA-based COVID -19 vaccines. In recent years, we at Lonza have amassed considerable expertise in the commercial manufacturing of mRNA and its encapsulation in Lipid Nanoparticles (LNP) at cGMP quality.
Content Type: Technical/Service brief
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center